Josep Font

Josep Font

Auto-generated profile, based on publicly available information

Josep Font

School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
QWQian Wang
Qian Wang
KBKimberley A. Beaumont
Kimberley A. Beaumont
NONicholas J. Otte
Nicholas J. Otte
JFJosep Font
Josep Font
Charles BaileyCharles Bailey
Charles Bailey
JHJeff Holst
Jeff Holst
Amino acids, especially leucine and glutamine, are important for tumor cell growth, survival and metabolism. A range of different transporters deliver each specific amino acid into cells, some of which are increased in cancer. These amino acids consequently activate the mTORC1 pathway and drive cell cycle progression. The leucine transporter LAT1/4F2hc heterodimer assembles as part of a large complex with the glutamine transporter ASCT2 to transport amino acids. In this study, we show that the expression of LAT1 and ASCT2 is significantly increased in human melanoma samples and is present in both BRAFWT (C8161 and WM852) and BRAFV600E mutant (1205Lu and 451Lu) melanoma cell lines. While inhibition of LAT1 by BCH did not suppress melanoma cell growth, the ASCT2 inhibitor BenSer significantly reduced both leucine and glutamine transport in melanoma cells, leading to inhibition of mTORC1 signaling. Cell proliferation and cell cycle progression were significantly reduced in the presence of BenSer in melanoma cells in 2D and 3D cell culture. This included reduced expression of the cell cycle regulators CDK1 and UBE2C. The importance of ASCT2 expression in melanoma was confirmed by shRNA knockdown, which inhibited glutamine uptake, mTORC1 signaling and cell proliferation. Taken together, our study demonstrates that ASCT2‐mediated glutamine transport is a potential therapeutic target for both BRAFWT and BRAFV600E melanoma.

13 October 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
RTReiya Taniguchi
Reiya Taniguchi
HKHideaki E. Kato
Hideaki E. Kato
JFJosep Font
Josep Font
CDChandrika N. Deshpande
Chandrika N. Deshpande
MWMiki Wada
Miki Wada
ONOsamu Nureki
Osamu Nureki
In vertebrates, the iron exporter ferroportin releases Fe2+ from cells into plasma, thereby maintaining iron homeostasis. The transport activity of ferroportin is suppressed by the peptide hormone hepcidin, which exhibits upregulated expression in chronic inflammation, causing iron-restrictive anaemia. However, due to the lack of structural information about ferroportin, the mechanisms of its iron transport and hepcidin-mediated regulation remain largely elusive. Here we report the crystal structures of a putative bacterial homologue of ferroportin, BbFPN, in both the outward- and inward-facing states. Despite undetectable sequence similarity, BbFPN adopts the major facilitator superfamily fold. A comparison of the two structures reveals that BbFPN undergoes an intra-domain conformational rearrangement during the transport cycle. We identify a substrate metal-binding site, based on structural and mutational analyses. Furthermore, the BbFPN structures suggest that a predicted hepcidin-binding site of ferroportin is located within its central cavity. Thus, BbFPN may be a valuable structural model for iron homeostasis regulation by ferroportin.

2 January 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAmanda J Scopelliti
Amanda J Scopelliti
JFJosep Font
Josep Font
Robert VandenbergRobert Vandenberg
Robert Vandenberg
OBOlga Boudker
Olga Boudker
RRRenae M Ryan
Renae M Ryan
Cancer cells undergo a shift in metabolism where they become reliant on nutrients such as the amino-acid glutamine. Glutamine enters the cell via the alanine/serine/cysteine transporter 2 (ASCT2) that is upregulated in several cancers to maintain an increased supply of this nutrient and are therefore an attractive target in cancer therapeutic development. ASCT2 belongs to the glutamate transporter (SLC1A) family but is the only transporter in this family able to transport glutamine. The structural basis for glutamine selectivity of ASCT2 is unknown. Here, we identify two amino-acid residues in the substrate-binding site that are responsible for conferring glutamine selectivity. We introduce corresponding mutations into a prokaryotic homologue of ASCT2 and solve four crystal structures, which reveal the structural basis for neutral amino acid and inhibitor binding in this family. This structural model of ASCT2 may provide a basis for future development of selective ASCT2 inhibitors to treat glutamine-dependent cancers.

24 January 2020 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
NFNatasha Freidman
Natasha Freidman
ICIchia Chen
Ichia Chen
QWQianyi Wu
Qianyi Wu
CBChelsea Briot
Chelsea Briot
JHJeff Holst
Jeff Holst
RRRenae Ryan
Renae Ryan

25 June 2010
Verified
Book Chapter
Closed access
PDF file
JFJosep Font
Josep Font
JMJoel P. Mackay
Joel P. Mackay

17 February 2021 in Nature
Verified
Journal Article
Closed access
PDF file
ICIchia Chen
Ichia Chen
SPShashank Pant
Shashank Pant
QWQianyi Wu
Qianyi Wu
RCRosemary J. Cater
Rosemary J. Cater
MSMeghna Sobti
Meghna Sobti
RRRenae M. Ryan
Renae M. Ryan